Patient-related acceptability of implementing preoperative screening for at-risk opioid and substance use

Funding

Findings reported in this publication were funded in whole by a SAMHSA State Opioid Response Grant under award number H79TI081712. The content is solely the responsibility of the authors and does not necessarily represent the official views of SAMHSA. Conflicts of interest: Dr. Bicket reports receiving grants from the National Institutes of Health, the Arnold Foundation, Michigan Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, the US Centers for Disease Control and Prevention, and the Patient-Centered Outcomes Research Institute during the conduct of the study, and past service as consultant for Axial Healthcare, outside the submitted work. Dr. Brummett serves as a consultant for Heron Therapeutics, a biotech company that produces a non-opioid analgesic for acute pain, and for Vertex Pharmaceuticals, and he served as a consultant for Alosa Health and the Benter Foundation. In addition, Dr. Brummett provides expert medicolegal testimony unrelated to this viewpoint. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, MDHHS, or SAMHSA.